Xingqi Pharmaceutical: SQ-129 vitreous body sustained-release injection has obtained clinical trial approval
I'm PortAI, I can summarize articles.
Xingqi Pharmaceutical announced that its developed SQ-129 vitreous sustained-release injection has received clinical trial approval from the National Medical Products Administration. This drug is a Class 2 modified new drug aimed at treating diabetic macular edema in adult patients and macular edema caused by retinal branch vein occlusion or central vein occlusion. Studies have shown that this drug has good safety and clinical development value, and currently, there are no similar products approved for market
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments